Close Menu

Icahn School of Medicine

The firm is engaged in multiple clinical validation trials and aims to raise more than $100 million to launch its Helio Liver Test in the US early next year.

A new study aims to compare the detection performance of Helio Health's circulating tumor DNA assay with that of other screening modalities.

The consortium is developing a real-time PCR test for host detection assays targeting epigenetic signatures and viral RNA for early-stage monitoring of potentially infected individuals.